Transparency in UK Clinical Trials After Brexit: Regulatory Shifts and Practical Realities

Transparency in clinical trials is central to building public trust, ensuring ethical compliance, and maintaining scientific credibility. In the European Union, the EU Clinical Trials Regulation (CTR) 536/2014 established strong requirements for publication of trial protocols and results through the Clinical Trials Information System (CTIS). Following Brexit, the United Kingdom (UK) has developed its own framework, which aligns with some EU principles but diverges in implementation.

Post-Brexit, UK sponsors must navigate a new landscape: MHRA guidance, Health Research Authority (HRA) requirements, and national registers such as ISRCTN. This article provides a critical commentary on how transparency obligations are evolving in the UK, the challenges sponsors face, and the potential long-term implications for global clinical development.

Background and Regulatory Framework

HRA Transparency Requirements

The HRA requires sponsors to register all clinical trials in a publicly accessible registry before enrolment begins. Results must be made publicly available within 12 months of trial completion, with penalties for non-compliance introduced in recent reforms.

MHRA Post-Brexit Guidance

MHRA maintains oversight of transparency obligations linked to Clinical Trial Authorisations (CTAs). Unlike EU CTIS, the UK currently relies on registries such as ISRCTN and EU Clinical Trials Register (for legacy trials), but MHRA has signalled plans for a UK-specific portal.

Global Harmonisation Challenges

UK divergence from EU systems poses challenges for multinational studies, requiring sponsors to duplicate registry entries and adapt to parallel reporting timelines.

Commentary on Key Transparency Challenges

Challenge 1 — Multiple Registries and Fragmentation

Post-Brexit, UK trials may need registration in ISRCTN, EU CTR (for EU sites), and potentially ClinicalTrials.gov for global compliance. This creates administrative duplication.
Commentary: Consolidation into a UK national portal could reduce burden, but until then, sponsors must invest in registry compliance teams.

Challenge 2 — Enforcement of Disclosure Rules

HRA audits reveal that a significant proportion of academic and NHS-sponsored trials fail to publish results on time.
Commentary: Stricter enforcement, including potential funding penalties, will likely improve compliance but may strain under-resourced NHS Trusts.

Challenge 3 — Balancing Transparency with Confidentiality

Sponsors express concerns about disclosing commercially sensitive information in early-stage trials.
Commentary: UK regulators emphasise patient safety and ethical obligations over commercial concerns, but guidance on redaction remains less prescriptive than the EU CTR.

Challenge 4 — Patient and Public Involvement

Transparency is not just about data—it involves communicating results in plain language summaries.
Commentary: The UK framework prioritises lay summaries, aligning with international trends, but challenges remain in standardising language for diverse populations.

Best Practices for Sponsors and Investigators

• Register trials prospectively on ISRCTN or other recognised registries.
• Plan for timely results publication (within 12 months of completion).
• Engage patients and the public in designing plain language summaries.
• Maintain version-controlled records in the Trial Master File (TMF) to demonstrate compliance.
• Audit registry compliance as part of trial governance processes.

Scientific and Regulatory Evidence

• Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
• HRA Transparency Strategy and Annual Reports
• MHRA Post-Brexit Guidance Documents
• ICH E6(R2) – Good Clinical Practice
• WHO ICTRP Registry Criteria

Special Considerations

• Oncology Trials: Transparency is critical for safety signal detection across global programmes.
• Pediatrics: Lay summaries for parents and children require tailored formats.
• Rare Diseases: Publication of small dataset trials raises confidentiality risks for participants.
• Decentralised Trials: Transparency of digital endpoints and patient-reported outcomes is a growing focus for regulators.

When Sponsors Should Seek Regulatory Advice

• If unsure about dual registration requirements for UK-EU trials.
• When publishing sensitive biomarker or genetic data.
• If academic sponsors lack resources for timely compliance.
• For first-in-human studies requiring confidentiality safeguards.

FAQs

1. What is the UK’s main clinical trial registry post-Brexit?

ISRCTN is commonly used, though legacy trials may remain in EUCTR. A UK-specific portal is under development.

2. How quickly must results be disclosed?

Within 12 months of trial completion, as required by HRA and MHRA guidance.

3. Are plain language summaries required in the UK?

Yes, HRA mandates lay summaries for patient and public communication.

4. Does Brexit change EUCTR obligations?

Yes. UK-only trials no longer use CTIS, but EU trials including UK sites must comply with both EU and UK rules.

5. What happens if sponsors fail to publish results?

Non-compliance may lead to HRA audits, reputational damage, or funding penalties for academic sponsors.

6. Do CROs play a role in transparency compliance?

Yes, CROs often manage registry entries and ensure documentation is uploaded to TMFs.

7. How does transparency support public trust?

By ensuring participants and the public see results, reinforcing the ethical justification for trial participation.

Conclusion

UK clinical trial transparency obligations post-Brexit are evolving toward a more independent system, while still aligned with global expectations. Sponsors must manage fragmented registry requirements, stricter enforcement by HRA, and the need for plain language communication. Early planning, strong CRO support, and proactive dialogue with regulators are essential to maintain compliance and public confidence in the UK research environment.

Transparency Obligations for Clinical Trials in the United Kingdom

Clinical trial transparency is central to ensuring public trust, ethical integrity, and scientific accountability in the United Kingdom (UK). Sponsors are required to register, disclose, and report results of trials involving investigational medicinal products (IMPs). Transparency obligations are enforced by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), with support from Research Ethics Committees (RECs). Since Brexit, the UK operates independently from the EU Clinical Trial Regulation (CTR 536/2014), but it continues to uphold high standards of trial transparency aligned with international norms such as WHO, ICMJE, and ICH E6(R2). These requirements ensure participants, researchers, and regulators have access to reliable and publicly available trial data, contributing to evidence-based healthcare.

This article outlines UK clinical trial transparency requirements, their regulatory framework, practical obligations for sponsors, and strategies to meet compliance standards.

Background and Regulatory Framework

UK Policy on Transparency

The HRA requires all clinical trials conducted in the UK to be registered in a publicly accessible database, such as ISRCTN or ClinicalTrials.gov, before the first participant is enrolled. MHRA complements this with requirements for timely disclosure of results.

Post-Brexit Developments

Post-Brexit, the UK continues to recognize transparency as a priority, even as it diverges from EU systems such as CTIS. Sponsors must now ensure compliance with UK-specific transparency expectations while maintaining alignment with global reporting obligations.

Ethical Foundations

Transparency is embedded in the ethical principle of respect for participants, ensuring that trial outcomes—positive or negative—are publicly accessible for the benefit of science and society.

Core Clinical Trial Insights: Transparency Requirements

1. Trial Registration

All trials must be registered on a WHO-recognized platform before recruitment begins. This ensures public visibility of trial objectives, methodologies, and eligibility criteria.

2. Results Disclosure

Sponsors must publish results within 12 months of trial completion. Lay summaries should accompany technical reports, ensuring accessibility to non-expert audiences.

3. HRA and MHRA Oversight

The HRA monitors compliance with trial registration and results reporting. MHRA inspections frequently review transparency obligations as part of Good Clinical Practice (GCP) assessments.

4. Academic and Investigator-Initiated Trials

Universities and NHS Trusts are expected to meet the same transparency standards as industry sponsors. Case studies reveal that academic trials often lag in timely disclosure, creating reputational and compliance risks.

5. Public Disclosure of Protocols

HRA policy encourages disclosure of trial protocols and amendments, enabling peer scrutiny and alignment with international standards.

6. Data Sharing Commitments

Transparency extends beyond trial registration and results. Sponsors are expected to provide access to anonymized datasets, ensuring compliance with GDPR and safeguarding participant privacy.

7. Inspection Findings

Common findings from MHRA inspections include:

• Unregistered investigator-initiated trials
• Delayed publication of trial results
• Incomplete or missing lay summaries
• Lack of SOPs for transparency compliance

Best Practices & Preventive Measures

• Register trials promptly on ISRCTN or ClinicalTrials.gov.
• Develop SOPs for trial disclosure and results reporting.
• Prepare plain-language lay summaries aligned with HRA guidance.
• Audit trial registries regularly to ensure compliance.
• Engage transparency officers or compliance teams to monitor obligations.

Scientific and Regulatory Evidence

• Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
• HRA Transparency Strategy
• ICH E6(R2) – Good Clinical Practice
• WHO Joint Statement on Trial Registration
• MHRA inspection reports on trial transparency

Special Considerations

Transparency requirements apply differently across trial types:

• Oncology: High public interest requires rapid disclosure of results.
• Pediatrics: Lay summaries must be tailored to parents and guardians.
• Rare Diseases: Data sharing is vital to advance knowledge in small populations.
• Decentralized Trials: Transparency obligations include disclosure of digital endpoints and remote data collection methods.

When Sponsors Should Seek Regulatory Advice

• If uncertain about registry selection or dual-registration obligations.
• When preparing lay summaries for complex therapeutic areas.
• If facing challenges harmonizing global and UK-specific disclosure requirements.
• For investigator-initiated trials with limited compliance resources.
• When inspection findings reveal gaps in transparency compliance.

FAQs

1. Is trial registration mandatory in the UK?

Yes. All trials must be registered on a WHO-recognized platform before participant enrollment begins.

2. How soon must results be disclosed?

Results must be published within 12 months of trial completion, with lay summaries provided for public understanding.

3. Which agencies oversee trial transparency in the UK?

Transparency is overseen by the HRA, with MHRA including it in GCP inspections.

4. Do transparency obligations apply to academic trials?

Yes. Investigator-initiated trials must meet the same standards as industry-sponsored studies.

5. How does GDPR affect trial transparency?

Data sharing must comply with GDPR, ensuring that participant privacy is protected through anonymization.

6. What are common transparency compliance issues?

Unregistered trials, delayed result postings, and missing lay summaries are frequent inspection findings.

7. Does Brexit change UK transparency rules?

While the UK no longer uses CTIS, it continues to enforce strong transparency obligations via HRA and MHRA policies.

Conclusion

UK clinical trial transparency requirements reflect the country’s commitment to openness, accountability, and public trust in research. Sponsors, CROs, and academic institutions must ensure timely registration, disclosure, and lay summaries for all trials. Post-Brexit independence has not diminished these obligations; rather, the UK continues to align with international best practices. By implementing strong compliance frameworks and engaging proactively with regulators, sponsors can avoid inspection findings and enhance the credibility of their research.